Prostate cancer (prevention) - dutasteride [ID75]
In development [GID-TAG409] Expected publication date: TBC
Search results
673 results
-
-
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
In development [GID-TAG411] Expected publication date: TBC
-
Obesity - lorcaserin [ID337]
In development [GID-TAG420] Expected publication date: TBC
-
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]
In development [GID-TAG369] Expected publication date: TBC
-
Pancreatic cancer - capecitabine [ID389]
In development [GID-TAG394] Expected publication date: TBC
-
Melanoma (advanced and metastatic) - temozolomide [ID316]
In development [GID-TAG401] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
In development [GID-TAG406] Expected publication date: TBC
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Proposed [GID-TA10668] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
In development [GID-TA10121] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
In development [GID-TA10473] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
In development [GID-TA10465] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
In development [GID-TA10502] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
In development [GID-TA10138] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
In development [GID-TA10140] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]
In development [GID-TA10144] Expected publication date: TBC
-
NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)
In development [GID-TA10183] Expected publication date: TBC
-
Nivolumab for treating recurrent glioblastoma [ID998]
In development [GID-TA10126] Expected publication date: TBC
-
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
In development [GID-TAG221] Expected publication date: TBC
-
Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]
In development [GID-TA10688] Expected publication date: TBC
-
The Assurance Nasal Alar SpO2 Sensor (discontinued)
In development [GID-MT510] Expected publication date: TBC
-
NBTXR-3 for treating soft tissue sarcoma [ID1050]
In development [GID-TA10226] Expected publication date: TBC
-
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
In development [GID-TA10452] Expected publication date: TBC
-
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
In development [GID-MT517] Expected publication date: TBC
-
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
In development [GID-TA10248] Expected publication date: TBC
-
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
In development [GID-TA10148] Expected publication date: TBC
-
Nivolumab with radiation therapy for untreated glioblastoma ID1562
In development [GID-TA10443] Expected publication date: TBC
-
Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)
In development [GID-TA10233] Expected publication date: TBC
-
Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]
In development [GID-TA10224] Expected publication date: TBC
-
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470
In development [GID-TA10354] Expected publication date: TBC
-
Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]
In development [GID-TA10625] Expected publication date: TBC
-
Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]
In development [GID-TA10447] Expected publication date: TBC
-
Eculizumab for treating refractory myasthenia gravis [ID1064]
In development [GID-TA10176] Expected publication date: TBC
-
Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]
In development [GID-TA10628] Expected publication date: TBC
-
Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]
In development [GID-TA10627] Expected publication date: TBC
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413
In development [GID-TA10329] Expected publication date: TBC
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178
In development [GID-TA10199] Expected publication date: TBC
-
Ranibizumab for treating diabetic retinopathy [ID1592]
In development [GID-TA10521] Expected publication date: TBC
-
Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]
In development [GID-TA10277] Expected publication date: TBC
-
Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)
In development [GID-TA10366] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
In development [GID-TA10186] Expected publication date: TBC
-
Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347
In development [GID-TA10264] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168
In development [GID-TA10208] Expected publication date: TBC
-
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
In development [GID-TA10211] Expected publication date: TBC